Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

04.07.2022

1 Arch Phys Med Rehabil
2 J Neurol
1 Magn Reson Med
4 Mult Scler
2 Neurology
2 PLoS One



    Arch Phys Med Rehabil

  1. MOUMDJIAN L, Smedal T, Arntzen EC, van der Linden ML, et al
    The impact of the COVID-19 pandemic on physical activity and associated technology use in persons with multiple sclerosis: an international RIMS-SIG Mobility survey study.
    Arch Phys Med Rehabil. 2022 Jun 24. pii: S0003-9993(22)00478.
    >> Share


    J Neurol

  2. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
    Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
    >> Share

  3. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
    >> Share


    Magn Reson Med

  4. MA YJ, Jang H, Lombardi AF, Corey-Bloom J, et al
    Myelin water imaging using a short-TR adiabatic inversion-recovery (STAIR) sequence.
    Magn Reson Med. 2022;88:1156-1169.
    >> Share


    Mult Scler

  5. PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
    A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
    Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
    >> Share

  6. CREE BA, Selmaj KW, Steinman L, Comi G, et al
    Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
    >> Share

  7. MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
    Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
    >> Share

  8. MAGNE F, Cellerino M, Balletto E, Aluan K, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
    >> Share


    Neurology

  9. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
    The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
    Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
    >> Share

  10. TOOSY AT, Eshaghi A
    Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
    Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
    >> Share


    PLoS One

  11. RASKIN E, Achiron A, Zloto O, Neuman R, et al
    Uveitis prior to clinical presentation of Multiple Sclerosis (MS) is associated with better MS prognosis.
    PLoS One. 2022;17:e0264918.
    >> Share

  12. PETRZALKA M, Meluzinova E, Libertinova J, Mojzisova H, et al
    IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.
    PLoS One. 2022;17:e0270607.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016